BofA raised the firm’s price target on Hutchmed (HCM) to $28 from $27 and keeps a Buy rating on the shares. The firm updated its model to include a revenue build for tazemetostat and adjust expectations slightly for operating expenses, the analyst tells investors in an earnings preview for its small-to-mid cap biotech coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM: